All In Biotech

Drug Trial Radar · NCT02127970

Single Dose vs. Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections

A Phase 3b, Double-Blind, Multicenter, Randomized Study to Compare the Efficacy and Safety of Single Dose Dalbavancin to a Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections

Last checked: Nov 19, 2026Latest source record: Sep 28, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 698 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

698

Actual

Start

Apr 18, 2014

Primary completion

Mar 11, 2015

Study completion Mar 11, 2015

Sponsor

Sponsor type
Industry
First posted
May 1, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To compare the efficacy of treatment with a single dose of dalbavancin 1500 mg to treatment with a two dose regimen of dalbavancin (1000 mg on Day 1 followed by 500 mg on Day 8) in participants with known or suspected Gram-positive acute bacterial skin and skin structure infections (ABSSSI) at 48 -72 hours after initiation of treatment.

Conditions

  • Abscess
  • Wound Infection
  • Surgical Site Infection
  • Cellulitis

Interventions

  • DalbavancinDrug

    Dalbavancin IV infusion over 30 minutes.

  • Dalbavancin-matching PlaceboDrug

    Dalbavancin-matching placebo IV infusion over 30 minutes.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Who Were Clinical Responders 48-72 Hours After the Initiation of Study DrugTime frame: Up to 48-72 hours after the initiation of study drug

Locations

78 sites in 12 countries. Site status is shown where the registry gives one.

  • 110

    Montgomery, Alabama

  • 103

    Anaheim, California

  • 117

    Long Beach, California

  • 106

    Long Beach, California

  • 118

    Modesto, California

  • 104

    San Diego, California

  • 113

    San Diego, California

  • 115

    San Diego, California

  • 116

    San Diego, California

  • 108

    Stockton, California

  • 105

    Sylmar, California

  • 112

    Washington D.C., District of Columbia

  • 107

    Orlando, Florida

  • 120

    Saint Cloud, Florida

  • 114

    Augusta, Georgia

  • 122

    Columbus, Georgia

  • 125

    Savannah, Georgia

  • 119

    Eunice, Louisiana

  • 101

    Springfield, Massachusetts

  • 109

    Detroit, Michigan

  • 121

    Butte, Montana

  • 123

    Omaha, Nebraska

  • 111

    Toledo, Ohio

  • 126

    Franklin, Tennessee

  • 127

    Smyrna, Tennessee

  • 802

    Sofia, Bulgaria

  • 800

    Sofia, Bulgaria

  • 801

    Sofia, Bulgaria

  • 200

    Zagreb, Croatia

  • 201

    Zagreb, Croatia

  • 253

    Tallinn, Estonia

  • 252

    Tallinn, Estonia

  • 251

    Tartu, Estonia

  • 302

    Kutaisi, Georgia

  • 303

    Tbilisi, Georgia

  • 300

    Tbilisi, Georgia

  • 301

    Tbilisi, Georgia

  • 352

    Debrecen, Hungary

  • 353

    Kaposvár, Hungary

  • 354

    Pécs, Hungary

Showing 40 of 78 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.